SANUWAVE Health, Inc. — 2022 Form 10-K
Reporting period: Fiscal year ended December 31, 2022. The filing reports annual results; it does not provide a clear standalone fourth-quarter income statement. Amounts below are in U.S. dollars.
Business context
SANUWAVE develops and sells noninvasive ultrasound and acoustic shock-wave medical systems, principally UltraMIST and PACE products for wound care and other regenerative-medicine uses. The company’s sales are primarily in the United States. UltraMIST sales and related accessories were the main reported growth drivers.
Key financial results and liquidity
| Metric | 2022 | 2021 |
|---|---|---|
| Revenue | $16.742 million | $13.010 million |
| Gross profit / gross margin | $12.411 million / 74% | $8.024 million / 62% |
| Operating loss | $8.952 million | $14.142 million |
| Net loss | $10.293 million; $0.02 per share | $27.259 million; $0.05 per share |
| Cash used in operating activities | $17.169 million | $6.409 million |
| Cash at year-end | $1.153 million | $0.619 million |
- Revenue increased 29%. Management attributed improved gross margin primarily to the higher mix of UltraMIST and higher-margin single-use accessories.
- Operating loss narrowed 37%, alongside lower selling and marketing and research and development spending. General and administrative expense rose 7%, mainly on legal and patent-related costs.
- Net loss improved substantially, but results include a $16.654 million noncash gain from changes in derivative fair value. Interest expense increased to $14.132 million from $7.095 million, reflecting higher debt and financing costs.
- Total assets were $19.873 million and total liabilities were $60.883 million at year-end; stockholders’ deficit was $41.010 million. Current assets of $6.620 million were far below current liabilities of $60.187 million.
- Senior secured debt had $19.211 million principal outstanding and was in default for minimum-liquidity covenant violations; its carrying value was $14.416 million after discount. The company also reported $24.122 million carrying value of convertible notes and $2.130 million in factoring liabilities.
Material changes and unusual items
- The company restated its 2022 first-, second-, and third-quarter financial information after identifying material errors involving shares issued for services, asset-sale accounting under a financing arrangement, unrecorded vendor invoices, senior-debt interest, and an inventory adjustment. Earlier interim reports and related communications should not be relied upon.
- August and November financings involved convertible notes with aggregate principal of $20.2 million, including refinanced amounts. Notes bear 15% interest and generally convert at $0.04 per share, subject to adjustments. Related warrants included two tranches exercisable for 504.4 million shares each. Year-end common shares outstanding were 548.7 million; the filing describes substantial potential dilution from warrants and convertible securities.
- The auditor issued an unqualified opinion on the financial statements but included a going-concern explanatory paragraph. The auditor did not express an opinion on internal control over financial reporting.
- Management identified material weaknesses in accounting and IT controls and concluded disclosure controls were ineffective at December 31, 2022. Remediation was underway but not complete.
Outlook, risks, and contingencies
- Management stated a goal of achieving positive operating cash flow in the first half of 2023 through UltraMIST and PACE growth and spending discipline. This is a stated objective, not quantified formal guidance.
- The company said it needs additional capital and plans to pursue financing, including warrant conversion or issuance of equity or debt, and possible strategic-partner investment. It warned financing may not be available on acceptable terms and could significantly dilute shareholders. Management and the auditor cited substantial doubt about the company’s ability to continue as a going concern for at least 12 months from filing.
- Other risks include debt defaults and high interest costs, dependence on financing, limited cash, supplier concentration and supply disruption, uncertain reimbursement and market acceptance, competition, regulatory requirements, and possible dilution. The company cited COVID-related disruption and limits on hospital procedures and clinical activities, alongside supply-channel effects associated with the war in Ukraine.
- A dispute with Celularity concerning compliance with the UltraMIST-related license agreement remained unresolved; the company denied breach and asserted counterclaims. The filing said the outcome and potential impact could not be determined. The company also disclosed ordinary-course legal matters without estimating a clear material exposure.
Investor verification priorities
- Confirm the restated quarterly figures and the full scope of accounting errors, and track remediation of material control weaknesses.
- Assess near-term cash needs, debt-default status, covenant relief, financing availability, and the timing and terms of any capital raise.
- Review the conversion, price-adjustment, and warrant provisions to assess potential dilution relative to outstanding shares.
- Monitor whether revenue growth and improved gross margin translate into lower operating cash burn and the stated positive-cash-flow goal.
- Track the Celularity license dispute, supplier continuity, reimbursement access, and regulatory or commercial progress for key products.